Advice
in the absence of a submission from the holder of the marketing authorisation
denosumab (Prolia®) is not recommended for use within NHS Scotland.
Indication under review: osteoporosis in men at increased risk of fractures
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
NICE (National Institute for Health and Clinical Excellence) is currently undertaking a multiple technology appraisal (MTA) that includes the use of denosumab in this indication. However, due to the significant time interval between product availability and the expected date of NICE guidance, not recommended advice has been issued.
Download detailed advice110KB (PDF)
Medicine details
- Medicine name:
- denosumab (Prolia)
- SMC ID:
- 1013/14
- Indication:
- Osteoporosis in men at increased risk of fractures
- Pharmaceutical company
- Amgen Ltd
- BNF chapter
- Endocrine system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 10 November 2014